Advanced search
1 file | 226.46 KB

Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment

Wim Ceelen (UGent) and Marc Bracke (UGent)
(2009) LANCET ONCOLOGY. 10(1). p.72-79
Author
Organization
Abstract
Roughly one in five patients with colorectal. cancer develops peritoneal minimal residual disease after surgical resection, and about one in seven patients develops peritoneal carcinomatosis. By contrast with the vast body of research addressing haematogenous metastasis, little is known about the biology of peritoneal spread of colorectal cancer. The development of peritoneal carcinomatosis involves well-defined steps including cell shedding and transport, adhesion to the mesothelial layer, invasion of and proliferation into the submesothelial stroma, and potential access to the systemic circulation. In this Review, we summarise the molecular mechanisms and potential preventive measures associated with each step of the peritoneal metastatic cascade.
Keywords
INTRAPERITONEAL CHEMOTHERAPY, COLON-CANCER, ALPHA-V-BETA-3 INTEGRINS, SYSTEMIC CHEMOTHERAPY, ADHESION MOLECULES, TUMOR-GROWTH, IN-VITRO, POLYMERASE-CHAIN-REACTION, HUMAN MESOTHELIAL CELLS, OVARIAN-CARCINOMA CELLS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 226.46 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Ceelen, Wim, and Marc Bracke. 2009. “Peritoneal Minimal Residual Disease in Colorectal Cancer: Mechanisms, Prevention, and Treatment.” Lancet Oncology 10 (1): 72–79.
APA
Ceelen, Wim, & Bracke, M. (2009). Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. LANCET ONCOLOGY, 10(1), 72–79.
Vancouver
1.
Ceelen W, Bracke M. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. LANCET ONCOLOGY. 2009;10(1):72–9.
MLA
Ceelen, Wim, and Marc Bracke. “Peritoneal Minimal Residual Disease in Colorectal Cancer: Mechanisms, Prevention, and Treatment.” LANCET ONCOLOGY 10.1 (2009): 72–79. Print.
@article{700352,
  abstract     = {Roughly one in five patients with colorectal. cancer develops peritoneal minimal residual disease after surgical resection, and about one in seven patients develops peritoneal carcinomatosis. By contrast with the vast body of research addressing haematogenous metastasis, little is known about the biology of peritoneal spread of colorectal cancer. The development of peritoneal carcinomatosis involves well-defined steps including cell shedding and transport, adhesion to the mesothelial layer, invasion of and proliferation into the submesothelial stroma, and potential access to the systemic circulation. In this Review, we summarise the molecular mechanisms and potential preventive measures associated with each step of the peritoneal metastatic cascade.},
  author       = {Ceelen, Wim and Bracke, Marc},
  issn         = {1470-2045},
  journal      = {LANCET ONCOLOGY},
  keyword      = {INTRAPERITONEAL CHEMOTHERAPY,COLON-CANCER,ALPHA-V-BETA-3 INTEGRINS,SYSTEMIC CHEMOTHERAPY,ADHESION MOLECULES,TUMOR-GROWTH,IN-VITRO,POLYMERASE-CHAIN-REACTION,HUMAN MESOTHELIAL CELLS,OVARIAN-CARCINOMA CELLS},
  language     = {eng},
  number       = {1},
  pages        = {72--79},
  title        = {Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment},
  url          = {http://dx.doi.org/10.1016/S1470-2045(08)70335-8},
  volume       = {10},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: